These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 4742680)

  • 41. [A comparison of the effects of the combined therapy with CPM+1321 TH+CS, KM+1321 TH+CS and KM+1314 TH+CS in the treatment of pulmonary tuberculosis].
    Iizuka Y; Iwasaki T; Fujioka K
    Kekkaku; 1969 Mar; 44(3):109-15. PubMed ID: 5783307
    [No Abstract]   [Full Text] [Related]  

  • 42. [Side effects of antibacterial drugs in the clinical course of pulmonary tuberculosis].
    Czkwianianc M; Markiewicz I
    Przegl Lek; 1969 Jun; 25(6):479-81. PubMed ID: 5805095
    [No Abstract]   [Full Text] [Related]  

  • 43. [Optimization of indirect endolymphatic injection of isoniazid in pulmonary tuberculosis].
    Peleneva IM; Gariaeva NA; Burukhina LV; Zavgorodniĭ IG; Shurygin AA; Gorovits GA; Miroshnikova IP; Barlamov OP
    Probl Tuberk; 2002; (11):24-6. PubMed ID: 12501792
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics of isoniazid in pulmonary tuberculosis--a comparative study at two dose levels.
    Roy V; Tekur U; Chopra K
    Indian Pediatr; 1996 Apr; 33(4):287-91. PubMed ID: 8772902
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Biophysical methods of diagnosis of drug allergy in patients with pulmonary tuberculosis].
    Shutskaia EI; Kamenskaia VV; Kashafutdinova ZN; Kolpakova TA; Zelinskiĭ IuG
    Probl Tuberk; 1982 Apr; (4):63-6. PubMed ID: 7088944
    [No Abstract]   [Full Text] [Related]  

  • 46. [Tuberculostatic preparations of the 2d series in the clinical treatment of pulmonary tuberculosis].
    Kaminskaia AA; Utkin VV; Korotaev GA; Golitsina LV
    Probl Tuberk; 1967; 45(5):29-33. PubMed ID: 5617941
    [No Abstract]   [Full Text] [Related]  

  • 47. [Experimental and scintigraphic study of aerosol therapy, particularly in pulmonary tuberculosis].
    Dumon G; Pastor J; Roul M; Brouillet-Gabriel MT; Dumon JF
    Mars Med; 1967; 104(11):891-9. PubMed ID: 5634099
    [No Abstract]   [Full Text] [Related]  

  • 48. [Clinico-roentgenologic control of treatment of pulmonary tuberculosis patients with endobronchial infusions of antitubercular preparations].
    Bezvershenko EA
    Vrach Delo; 1969; 12():81-5. PubMed ID: 5375640
    [No Abstract]   [Full Text] [Related]  

  • 49. Neuroimaging findings in isoniazid central nervous system toxicity, presumed intramyelinic edema.
    Hawkes M; Kitai I; Blaser S; Cohen E; Bitnun A; Fluss J; Tran D
    Eur J Paediatr Neurol; 2008 Nov; 12(6):512-5. PubMed ID: 18243740
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Controversy over tuberculosis therapy in HIV infected patients. Isoniazide therapy--brief chemotherapy].
    Arnheim K
    Fortschr Med; 1995 Dec; 113(35-36):14-5. PubMed ID: 8582689
    [No Abstract]   [Full Text] [Related]  

  • 51. [On therapeutic effects of morphazinamide, used alone and in association, in recent and chronic pulmonary tuberculosis].
    Pasargiklian M
    Minerva Med; 1965 Sep; 56(71):2855-62. PubMed ID: 5322267
    [No Abstract]   [Full Text] [Related]  

  • 52. Evaluation of isoniazid administration on pulmonary tuberculous patients with isoniazid-resistant strain.
    Oka S; Motomiya M; Sato H; Fujimoto M
    Sci Rep Res Inst Tohoku Univ Med; 1967 Nov; 14(3):177-80. PubMed ID: 4978373
    [No Abstract]   [Full Text] [Related]  

  • 53. [Results of short-term tuberculostatic treatment at the end of the therapeutic regimen].
    Tănase C; Baraneţchi C
    Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol; 1983; 32(1):43-7. PubMed ID: 6312534
    [No Abstract]   [Full Text] [Related]  

  • 54. Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, 1995-2002, after the implementation of DOTS-plus.
    Kam KM; Yip CW
    Int J Tuberc Lung Dis; 2004 Jun; 8(6):760-6. PubMed ID: 15182147
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Cycloserine content of the blood of patients with pulmonary tuberculosis].
    Birnbauer L; Karoi A
    Probl Tuberk; 1967; 45(2):72-6. PubMed ID: 5605652
    [No Abstract]   [Full Text] [Related]  

  • 56. [Treatment of tuberculosis patients with massive bacterial excretion].
    Gavril'ev SS; Vinokurova MK
    Probl Tuberk; 1997; (2):17-8. PubMed ID: 9235572
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Practical tuberculostatic therapy].
    Hudson LD; Sbarbaro JA
    Fortschr Med; 1973 Nov; 91(32):1288. PubMed ID: 4751360
    [No Abstract]   [Full Text] [Related]  

  • 58. [The use of fenazid in patients with pulmonary tuberculosis with poor isoniazid tolerance].
    Borisova MI; Stakhanov VA; Sharkova TI; Ivashchenko NA
    Probl Tuberk Bolezn Legk; 2003; (7):34-7. PubMed ID: 12939876
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Serum concentrations of rifampicin and isoniazid in tuberculosis.
    Seth V; Beotra A; Seth SD; Semwal OP; Kabra S; Jain Y; Mukhopadhya S
    Indian Pediatr; 1993 Sep; 30(9):1091-8. PubMed ID: 8125594
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Susceptibility tests to second line drugs and re-treatment of tuberculosis revisiting early experiences.
    de Kantor IN; Barrera L
    Medicina (B Aires); 2007; 67(3):231-7. PubMed ID: 17628909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.